| Outcome |
Relative effect
(95% CI) |
Absolute effect
(95% CI)1 |
Certainty of the Evidence
(GRADE) |
Clinical improvement
D28 |
RR: 1.20
(0.99 - 1.46) |
109 more per 1000
(from 5 fewer to 251 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious
due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
| 1 trials
Gottlieb R, 2021
275 participants
|
|
Bamlanivimab+Etesevimab
656 per 1,000
(541 - 798) |
Placebo
547
per 1,000 |
|
Clinical improvement
D60 |
Outcome not yet measured or reported
|
|
Hospitalisation or death
* |
RR: 0.23
(0.11 - 0.49) |
50 fewer per 1000
(from 58 fewer to 33 fewer)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Serious
due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
| 2 trials
Dougan M, 2021 (1); Dougan M, 2021 (2)
1817 participants
|
|
Bamlanivimab+Etesevimab
15 per 1,000
(7 - 32) |
Placebo
65
per 1,000 |
|
WHO progression score (level 7 or above)
D28 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D60 |
Outcome not yet measured or reported
|
|
All-cause mortality
D28 |
RR: 0.05
(0.01 - 0.39) |
14 fewer per 1000
(from 15 fewer to 9 fewer)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Serious
due to low number of participants/events
|
| 3 trials
Dougan M, 2021 (1); Dougan M, 2021(2); Gottlieb R, 2021
2092 participants
|
|
Bamlanivimab+Etesevimab
1 per 1,000
(0 - 6) |
Placebo
15
per 1,000 |
|
All-cause mortality
D60 |
RR:
( - ) |
Zero events in both groups
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious
no events in both groups
|
| 1 trials
Gottlieb R, 2021
275 participants
|
|
Bamlanivimab+Etesevimab
0 per 1,000
( - ) |
Placebo
0
per 1,000 |
|
Viral negative conversion
D7 |
RR: 1.66
(1.21 - 2.29) |
59 more per 1000
(from 19 more to 116 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious
due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
| 2 trials
Dougan M, 2021 (1); Gottlieb R, 2021
1233 participants
|
|
Bamlanivimab+Etesevimab
149 per 1,000
(109 - 206) |
Placebo
90
per 1,000 |
|
Adverse events
|
RR: 0.91
(0.65 - 1.28) |
12 fewer per 1000
(from 47 fewer to 38 more)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Serious
due to low number of participants/events
|
| 3 trials
Dougan M, 2021 (1); Dougan M, 2021 (2); Gottlieb R, 2021
2092 participants
|
|
Bamlanivimab+Etesevimab
123 per 1,000
(88 - 173) |
Placebo
135
per 1,000 |
|
Serious adverse events
|
RR: 1.43
(0.59 - 3.45) |
4 more per 1000
(from 3 fewer to 21 more)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Serious
due to wide confidence interval consistent with the possibility for no effect/trivial effect and the possibility for harm
|
| 3 trials
Dougan M, 2021 (1); Dougan M, 2021 (2); Gottlieb R, 2021
2092 participants
|
|
Bamlanivimab+Etesevimab
12 per 1,000
(5 - 29) |
Placebo
9
per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
